Juvenile Myelomonocytic Leukemia Clinical Trials

53 clinical trials for Juvenile Myelomonocytic Leukemia across international registries, including 8 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT — RECRUITING · NA
• Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders — RECRUITING · PHASE2
• The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study — RECRUITING · PHASE1
• A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation — RECRUITING · PHASE1
• Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases — RECRUITING · PHASE2
• HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant — RECRUITING · PHASE1
• Study for Epidemiology and Characterization of Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leucemia (JMML) in Childhood — RECRUITING
• MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies — RECRUITING · PHASE2
• TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies — ACTIVE_NOT_RECRUITING · PHASE2
• Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia — ACTIVE_NOT_RECRUITING · PHASE2
• Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation — ACTIVE_NOT_RECRUITING · PHASE1
• A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies — COMPLETED · PHASE2
• Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation — ACTIVE_NOT_RECRUITING · PHASE2
• CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant — OTHER · PHASE1
• Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML) — COMPLETED · PHASE1
• Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis — ACTIVE_NOT_RECRUITING · PHASE3
• Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies — OTHER
• Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases — COMPLETED · PHASE3
• Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia — COMPLETED · PHASE1
• Yttrium-90 Anti CD66 Monoclonal Antibody in Childhood Relapsed/Refractory Leukaemia — COMPLETED · PHASE1
• Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer — COMPLETED · PHASE2
• Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia — COMPLETED · PHASE1
• Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation — COMPLETED · PHASE2
• Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies — COMPLETED · PHASE2
• Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer — COMPLETED · PHASE1
• Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies — COMPLETED · NA
• Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant — COMPLETED · PHASE1
• Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders — COMPLETED · NA
• Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies — COMPLETED · PHASE2
• Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant — COMPLETED · PHASE3
• Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies — COMPLETED · PHASE2
• Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia — COMPLETED · PHASE2
• Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer — COMPLETED
• Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer — COMPLETED · NA
• Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias — TERMINATED · PHASE1
• Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant — COMPLETED · PHASE2
• Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer — COMPLETED · PHASE2
• Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation — TERMINATED · PHASE2
• Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer — COMPLETED · NA
• Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS) — WITHDRAWN · PHASE1
• Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant — COMPLETED · NA
• T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant — TERMINATED · PHASE2
• A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies — COMPLETED · PHASE2
• Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML — TERMINATED · PHASE1
• Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia — COMPLETED · PHASE1
• MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia — COMPLETED · PHASE1
• Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies — COMPLETED · PHASE1
• Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic Leukemia — COMPLETED · PHASE2
• Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT) — OTHER · PHASE4
• Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies — COMPLETED · PHASE2

Refine this search